To The Moon

Financial Highlights: Net Loss Narrowed Significantly with Solid Cash Balance Jenscare (9877.HK), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, released interim results for 2024H1 ended June 30, 2024. Net Loss attributable to common shareholders was RMB 102 million[1] (US$ 14 million), narrowed down by 41.8% compared to the same period of last year. Cash[2] was RMB 922 million (US$ 129 million), which is sufficient for the future development of the Company to achieve its business strategy by advancing the global application of its Core Products, including carrying forward the clinical trial, the registration process, and market launch of the products. [1] Conversions from RMB to US$ is made at an excha

Disclaimer The information disclosed in this article is for academic communication purposes only and should not be construed as medical advice under any circumstances. We make no representations or warranties as to the accuracy, completeness or timeliness of all original, reproduced or shared content.  For any medical device mentioned in this article, our company does not make any commitment and guarantee on its performance and clinical performance in diagnosis and treatment activities. $健世科技-B(09877)$

Jenscare(9877.HK) 2023Q3 Newsletter Jenscare(9877.HK) 2023Q3 Newsletter $健世科技-B(09877)$

Jenscare(9877.HK) 2023Q2 Newsletter $健世科技-B(09877)$